arGEN-X’ Antibody Platform struck a new Dermatology alliance

22/05/2015 - 2 minutes

arGEN-X and LEO Pharma allied to develop innovative antibody-based solutions for the treatment of chronic inflammation underlying many skin conditions. The deal amounts to a total of €104.5M, from which arGEN-X will receive €4.5M as an upfront payment and up to €100M in royalties.

LEO Pharma will receive exclusive access to an already existing arGEN-X antibody for inflammation-related skin diseases currently still in preclinical development. The companies will co-fund product development costs up to clinical trial application filing.

arGEN-X’ platform, SIMPLE Antibody, exploits the unique characteristics of the llama immune system, an original approach that other companies are also adopting, such as Belgian Ablynx. Whilst proteins of therapeutic interest are often conserved between humans and rodents, they diverge enormously between humans and llamas. This makes llamas capable of producing high affinity antibody responses against any therapeutic target. Thanks to arGEN-X’ platform, the generated antibodies can display unattainable properties.

This new partnership harnesses the complementary expertise of both companies. LEO Pharma owns a vast expertise in bringing products to a market that meets the needs of dermatology patients,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member